Medicxi’s orexin dream deal

Why Medicxi, Heptares partnered to spin out orexin agonist programs

Sleep disorder spinouts Orexia Ltd. and Inexia Ltd. were created to marry Medicxi’s keen interest in agonizing orexin and Heptares Therapeutics Ltd.’s desire to find creative ways to fund its pipeline.

Medicxi will invest up to €40 million ($45.8 million) in a tranched investment across both companies, while the Sosei Group Corp.

Read the full 516 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE